United Therapeutics Corporation $UTHR Position Cut by Aurora Investment Counsel

Aurora Investment Counsel decreased its position in shares of United Therapeutics Corporation (NASDAQ:UTHR) by 81.2% in the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 858 shares of the biotechnology company’s stock after selling 3,696 shares during the quarter. Aurora Investment Counsel’s holdings in United Therapeutics were worth $509,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors also recently modified their holdings of the company. Sage Rhino Capital LLC grew its position in shares of United Therapeutics by 5.1% during the first quarter. Sage Rhino Capital LLC now owns 474 shares of the biotechnology company’s stock worth $281,000 after acquiring an additional 23 shares during the last quarter. Bryn Mawr Trust Advisors LLC increased its stake in shares of United Therapeutics by 5.4% in the first quarter. Bryn Mawr Trust Advisors LLC now owns 465 shares of the biotechnology company’s stock valued at $276,000 after purchasing an additional 24 shares during the period. Independent Advisor Alliance raised its holdings in shares of United Therapeutics by 3.3% during the fourth quarter. Independent Advisor Alliance now owns 833 shares of the biotechnology company’s stock valued at $406,000 after buying an additional 27 shares during the last quarter. Kera Capital Partners Inc. raised its holdings in shares of United Therapeutics by 6.1% during the first quarter. Kera Capital Partners Inc. now owns 471 shares of the biotechnology company’s stock valued at $279,000 after buying an additional 27 shares during the last quarter. Finally, Florida Financial Advisors LLC boosted its position in shares of United Therapeutics by 5.4% during the fourth quarter. Florida Financial Advisors LLC now owns 550 shares of the biotechnology company’s stock worth $268,000 after buying an additional 28 shares during the period. Institutional investors and hedge funds own 94.08% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages recently issued reports on UTHR. Weiss Ratings reissued a “buy (b)” rating on shares of United Therapeutics in a report on Thursday, June 11th. Bank of America cut their target price on United Therapeutics from $620.00 to $613.00 and set a “neutral” rating on the stock in a research note on Friday, July 10th. TD Cowen reiterated a “buy” rating on shares of United Therapeutics in a research report on Thursday, May 21st. Raymond James Financial initiated coverage on United Therapeutics in a research note on Friday, April 10th. They issued an “outperform” rating and a $700.00 price target for the company. Finally, Royal Bank Of Canada raised their price target on United Therapeutics from $701.00 to $704.00 and gave the company an “outperform” rating in a report on Tuesday, July 7th. Ten research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, United Therapeutics currently has an average rating of “Moderate Buy” and a consensus target price of $644.82.

United Therapeutics Price Performance

UTHR opened at $535.67 on Friday. The business has a 50 day moving average price of $552.38 and a two-hundred day moving average price of $530.14. The company has a market capitalization of $22.74 billion, a price-to-earnings ratio of 19.77, a price-to-earnings-growth ratio of 1.79 and a beta of 0.58. United Therapeutics Corporation has a 1-year low of $272.12 and a 1-year high of $609.35.

United Therapeutics (NASDAQ:UTHR) last issued its quarterly earnings results on Wednesday, May 6th. The biotechnology company reported $5.82 earnings per share (EPS) for the quarter, missing the consensus estimate of $7.00 by ($1.18). United Therapeutics had a net margin of 40.62% and a return on equity of 19.24%. The firm had revenue of $781.50 million for the quarter, compared to analyst estimates of $797.40 million. During the same quarter last year, the business posted $6.63 earnings per share. The firm’s revenue for the quarter was down 1.6% compared to the same quarter last year. Equities analysts expect that United Therapeutics Corporation will post 26.63 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, CFO James Edgemond sold 10,000 shares of United Therapeutics stock in a transaction dated Thursday, April 30th. The stock was sold at an average price of $572.61, for a total transaction of $5,726,100.00. Following the transaction, the chief financial officer directly owned 18,876 shares of the company’s stock, valued at $10,808,586.36. The trade was a 34.63% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders sold a total of 564,743 shares of company stock worth $316,423,257 over the last ninety days. Company insiders own 8.60% of the company’s stock.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.